RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Story so far
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- RAD Achieves Partial Response in Phase 1 Trial of RAD204
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
Earlier from Radiopharm Theranostics
- Notice of Extraordinary General Meeting and Proxy Form
- Share Purchase Plan - Now Open
- Update - Proposed issue of securities - RAD
- Application for quotation of securities - RAD
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Radiopharm Theranostics
- Change in substantial holding
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Ceasing to be a substantial holder
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics